Friday February 24th 2017: Eli Lilly and Company, LLY is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, Eli Lilly and Company, LLY has a market cap of 90.53 B. Since its IPO date on the 06/01/1972, Eli Lilly and Company, LLY performance year to date is 11.33%. Today Eli Lilly and Company, LLY has gained -0.21%, with a current price of 81.88.
Ownership of the company is 11.50% for insider ownership while institutional ownership is 77.60%. The management of the company have seen the company have a payout ratio of 99.20%. Return of assets are at 5.80%, with return on investment at 11.60%.
In terms of debt levels and profit levels, Eli Lilly and Company, LLY is seeing a long-term debt/equity of 0.54. While Total debt/equity is 0.73. With a profit margin of 10.10%, this is combined with a gross margin of 73.80%, and operating margin of 12.90%. Eli Lilly and Company ability to meet debt levels, with a current ratio of 1.2, while the quick ratio is 0.9.
For the last year Eli Lilly and Company, LLY has seen a EPS growth of 14.10%. A performance for the year of 10.28%. The 52-week high is -5.58%, and the 52-week low is 27.58%. The average volume for Eli Lilly and Company, LLY is 4903159.
With a target price of 88.95, can Eli Lilly and Company, LLY reach this target? Looking at the value indicators of Eli Lilly and Company, LLY. Eli Lilly and Company has a P/E of 39.77 and a forward P/E of 18.73. Perhaps the more useful indicator than P/E, is PEG which has a value of 3.11. Eli Lilly and Company also has a P/S and a P/B of 4.19 and 6.17 respectively. For P/cash, Eli Lilly and Company has a value of 25.82, while it is 28.69 for P/free cash flow.
At the current price of 81.88, Eli Lilly and Company has a dividend yield of 2.54%. We see a return on equity of 15.00%.
Looking more long-term Eli Lilly and Company, is projected to get an EPS growth for the next five years of 12.77%. In the short-term an EPS growth of 6.17% in the next year is forecasted. This is after a EPS growth of 14.10% for this year and for the last five years a -8.00% growth has been seen.